Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4501 X St
2nd Floor
Sacramento, CA 95817Phone+1 916-734-5959Fax+1 916-703-5265
Summary
- Dr. Edward Kim is a medical oncology physician scientist at the UC Davis Comprehensive Cancer Center where he specializes in gastrointestinal malignancies. He graduated from Harvard University and received his MD/PhD from Stony Brook University School of Medicine and has been in practice 12 years.
Education & Training
- University of MichiganFellowship, Hematology and Medical Oncology, 2007 - 2011
- University of MichiganResidency, Internal Medicine, 2005 - 2007
- Stony Brook University Health Sciences Center School of MedicineClass of 2005
- Harvard UniversityAB, Chemistry, Magna cum laude, 1993 - 1997
Certifications & Licensure
- CA State Medical License 2012 - 2026
- MI State Medical License 2005 - 2015
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
- RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) Start of enrollment: 2016 Aug 30
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer Start of enrollment: 2018 Oct 16
- Join now to see all
Publications & Presentations
PubMed
- 23 citationsPhase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma.Cara M. Kenney, Tricia F. Kunst, Santhana Webb, Devisser Christina, Christy Arrowood
Investigational New Drugs. 2021-01-06 - 88 citationsCharacterization of the metastasis-associated protein, S100A4. Roles of calcium binding and dimerization in cellular localization and interaction with myosin.Edward J. Kim, David M. Helfman
The Journal of Biological Chemistry. 2003-08-08 - 22 citationsRandomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancerRichard D. Kim, Shannon McDonough, Anthony B. El-Khoueiry, Tanios Bekaii-Saab, Stacey M. Stein
European Journal of Cancer. 2020-05-01
Press Mentions
- $3 Million National Grant to Fund Pancreatic Cancer StudyFebruary 7th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: